Journal article
Glycemic impact of gabapentin and Nucleo C.M.P in metformin-controlled diabetic patients: A case report
SAGE open medical case reports, v 12
Jul 2024
PMID: 39055669
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
This study examines the contraindications of gabapentin and Nucleo C.M.P Forte in metformin-controlled diabetic patients, focusing on their potential to induce hyperglycemia. A case report of a 65-year-old woman with type II diabetes is presented, demonstrating elevated blood glucose levels following the initiation of gabapentin and Nucleo C.M.P Forte. The literature review highlights limited data on gabapentin-induced hyperglycemia, with additional consideration of the potential effects of Nucleo C.M.P Forte. The study suggests modifying insulin therapy in diabetic patients taking gabapentin and calls for further research on this interaction.
Metrics
2 Record Views
Details
- Title
- Glycemic impact of gabapentin and Nucleo C.M.P in metformin-controlled diabetic patients: A case report
- Creators
- Hashim Talib Hashim - University of KerbalaAhmed Qasim Mohammed Alhatemi - Thi Qar UniversityNarjiss Aji - Drexel UniversityJaffer Shah - Mohammed V University
- Publication Details
- SAGE open medical case reports, v 12
- Publisher
- SAGE Publications
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:001275612000001
- Scopus ID
- 2-s2.0-85199344527
- Other Identifier
- 991022202085604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Pharmacology & Pharmacy